<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804930</url>
  </required_header>
  <id_info>
    <org_study_id>2018_87</org_study_id>
    <secondary_id>2020-A00566-33</secondary_id>
    <nct_id>NCT04804930</nct_id>
  </id_info>
  <brief_title>Trichoscopy and Systemic Scleroderma</brief_title>
  <acronym>TRICHLOSCLERO</acronym>
  <official_title>Prognostic Value of Trichoscopy in Patients With Systemic Scleroderma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Few data are available on scalp involvement in systemic scleroderma.&#xD;
&#xD;
        -  Few data are available on the association between scalp abnormalities and features of&#xD;
           systemic scleroderma&#xD;
&#xD;
        -  Trichoscopy is a simple, reproducible, noninvasive examination that is part of the&#xD;
           examination of hairy areas in routine dermatologic practice&#xD;
&#xD;
        -  There is a lack of simple, noninvasive examinations to evaluate patients with systemic&#xD;
           scleroderma&#xD;
&#xD;
      The objective will be to evaluate the contribution of trichoscopy in the evaluation of&#xD;
      patients with systemic scleroderma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of elementary lesions observed by trichoscopic assessment of the scalp</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparison of the frequencies of elementary lesions visualized in patients with systemic scleroderma and healthy subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between visceral damage of systemic scleroderma and trichoscopic features</measure>
    <time_frame>Baseline</time_frame>
    <description>Frequency of visceral damage of systemic scleroderma: pulmonary hypertension, lung fibrosis, kidney failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between global severity of systemic scleroderma and trichoscopic features</measure>
    <time_frame>Baseline</time_frame>
    <description>Correlation between EUSTAR score, Rodnan score, Medsger's score and trichoscopic features</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between autoimmune profile of sclerodermic patients and trichoscopic features</measure>
    <time_frame>Baseline</time_frame>
    <description>Correlation of antibodies, inflammatory profile of patients with trichoscopic features.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Scleroderma, Systemic</condition>
  <arm_group>
    <arm_group_label>patients with systemic scleroderma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy subject</arm_group_label>
    <description>healthy subject without systemic scleroderma or known hair or scalp disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>picture</intervention_name>
    <description>We will perform a non-invasive assessment of the scalp with a dermoscope by taking two standardized pictures on the frontal area and the occipital area in order to a blinded analysis of trichoscopic patterns</description>
    <arm_group_label>healthy subject</arm_group_label>
    <arm_group_label>patients with systemic scleroderma</arm_group_label>
    <other_name>Non-invasive trichoscopy: dermoscopic assessment of the scalp (picture)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with systemic scleroderma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who fulfils the Systemic scleroderma ACR-EULAR 2013 criteria&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Being social insured&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients aged less than 18 years old&#xD;
&#xD;
          -  patients under legal protection&#xD;
&#xD;
          -  patients deprived of their liberty&#xD;
&#xD;
          -  patients in emergency situations&#xD;
&#xD;
          -  patients who refused or unable to give informed consent&#xD;
&#xD;
          -  For the control group: sclap inflammatory disease active the day of the examination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Sobanski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent Sobanski, MD</last_name>
    <phone>0320445962</phone>
    <email>vincent.sobanski@chru-lille.fr</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trichoscopy</keyword>
  <keyword>Dermoscopy</keyword>
  <keyword>Systemic Scleroderma</keyword>
  <keyword>Scalp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

